Browse Category

Pharmaceuticals News 19 December 2025 - 21 December 2025

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

December 21, 2025 — AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 near multi‑month highs, but the weekend news cycle (starting December 20, 2025) has put a familiar theme back in the spotlight: U.S. drug pricing policy. At the same time, Wall Street’s newest notes show a market still split between strong fundamentals (Skyrizi/Rinvoq momentum and a dividend raise) and policy/pipeline debates that could shape sentiment into 2026. ABBV last traded around $226.82 after Friday’s session, up about 1.8% on the day, and sitting within striking distance of its 52‑week high. MarketWatch Where AbbVie stock stands as
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. (NASDAQ: AMGN) is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA approvals that expand the growth runway, reaffirmed shareholder returns via dividends, and a split—but active—Wall Street outlook heading into 2026. AMGN last traded around $327.38, reflecting the most recent available market print (U.S. markets are closed today). Below is a detailed, publication-ready breakdown of today’s key Amgen stock news, along with forecasts and analyst analysis relevant as of 20.12.2025. What’s
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Dec. 20, 2025 — Johnson & Johnson (NYSE: JNJ) is closing out the week with investors weighing a fresh talc-related jury verdict, a fast-moving U.S. drug-pricing policy push that could soon reach J&J, and a stream of late-2025 catalysts spanning FDA-related updates, M&A, and a major MedTech restructuring plan. JNJ shares last traded around $206.37, down about 0.9% from the prior close, after touching higher levels earlier in the week. The bigger picture: J&J has delivered a strong 2025 run by large-cap healthcare standards, with total return measures showing roughly high‑40% year-to-date performance by mid-to-late December. Finance Charts Johnson &
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company (NYSE: LLY) is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 (Dec. 19) after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis The bigger story isn’t just the price. Lilly entered the rarefied “$1 trillion market value” club this year—an inflection point for a pharmaceutical company—and it’s doing so on the back of a rapidly expanding obesity and cardiometabolic franchise, a pipeline
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) heads into the weekend of December 20, 2025 with investors still digesting a fast-moving sequence of catalysts: fresh clinical data for its lead program REC-4881, a notable JPMorgan upgrade, and a burst of unusually heavy trading volume that has kept the stock in the spotlight. Because U.S. markets are closed on Saturday, the most recent trading reference is Friday’s close (Dec. 19, 2025). RXRX last traded around $4.26 after a volatile week that included a one-day surge and a quick pullback. StockAnalysis RXRX stock price action this week: the “upgrade pop” meets reality checks RXRX’s
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Inc. stock (NYSE: PFE) is ending the week in a familiar place: the mid-$20s. But the story behind that “quiet” price is anything but quiet. Investors are weighing Pfizer’s newly issued 2026 outlook, an evolving U.S. drug-pricing landscape tied to the TrumpRx / most-favored-nation (MFN) framework, and a pipeline-and-deal strategy meant to carry the company through a multi-year patent cliff and the long fade of COVID-era revenue. Reuters+1 Pfizer stock price snapshot: where PFE stands on Dec. 20, 2025 With U.S. markets closed for the weekend, the latest available quote has Pfizer shares around $25.19, after a volatile stretch
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday, December 19, 2025, on a strong note and then stayed relatively steady in after-hours trading—setting up a familiar “what happens next?” question for investors heading into the final full week before year-end. Below is a detailed rundown of what moved VRTX today, what the after-hours tape is saying, what analysts are forecasting right now, and the key catalysts to watch before the next U.S. market open (Monday, December 22, 2025). VRTX after the bell: where the stock closed and how it traded after hours VRTX rose 1.97% in the regular session to close
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended Friday, December 19, 2025, with a sharp, high-volume move that kept traders focused into the after-hours session. The headline drivers were a new U.S. government pricing agreement tied to TrumpRx.gov and tariff relief, plus a fresh U.K. regulatory approval for lenacapavir—two catalysts that hit the tape on the same day and helped explain why Gilead was among the stronger large-cap pharma names into the close. Gilead stock price recap after the bell (Dec. 19 close + after-hours) Gilead’s regular session finished firmly higher, and the after-hours tape stayed constructive but calm. One notable detail:
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets. Below is what happened after the bell, why it matters, and the key items to track before the next U.S. market open (Monday, Dec. 22, 2025). MRK stock price after the bell: the key numbers Merck shares closed at $101.09, up $0.40 (+0.40%) on Friday. Zacks+1 In after-hours trading, MRK was slightly lower, trading around $100.9–$101.0 in early evening
Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly and Company (NYSE: LLY) ended Friday, December 19, 2025, with a solid gain, then barely budged in after-hours trading—an important clue about how investors are digesting the latest wave of obesity-drug headlines heading into next week. One key calendar note up front: U.S. stock markets do not open on Saturdays. With December 19 falling on a Friday, the next regular stock-market open is Monday, December 22, 2025 (barring any exchange-specific changes). LLY stock price after the bell: how Eli Lilly traded after hours on Dec. 19 That “strong close / quiet after-hours” pattern typically signals that Friday’s move
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) is ending the week with investors weighing a cautious 2026 outlook against fresh pipeline momentum and a fast-moving U.S. drug-pricing policy backdrop. As of the latest available quote on Friday, Dec. 19, 2025, Pfizer shares traded around $25.37, up about 1.3% on the day, with an intraday range of roughly $24.99 to $25.52 and volume near 43.5 million shares. Below is what’s driving Pfizer stock right now, what management and analysts are forecasting, and what catalysts investors are watching into 2026. Pfizer stock price action on Dec. 19, 2025: why PFE is in focus Pfizer’s share
Merck (MRK) Stock News and Forecasts for Dec. 19, 2025: Drug-Pricing Deals, FDA Fast-Track Catalysts, and Wall Street Targets

Merck (MRK) Stock News and Forecasts for Dec. 19, 2025: Drug-Pricing Deals, FDA Fast-Track Catalysts, and Wall Street Targets

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 19, 2025, as investors balanced two big forces that tend to move large-cap pharma: U.S. drug-pricing policy headlines and pipeline-driven growth prospects. Shares were around $101.71, up about 1% from the prior close, as the market digested White House signals on new pricing agreements and fresh read-throughs from late-2025 clinical and regulatory developments. Below is a comprehensive, news-style breakdown of what’s driving Merck stock right now, what analysts are forecasting, and the key catalysts investors are tracking into 2026—based on reporting and company statements available on 19.12.2025. Where
1 33 34 35 36 37 56

Stock Market Today

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

7 February 2026
Macquarie Group shares fell 2.17% to A$207.83 Friday, marking a third straight decline as the ASX 200 slid 2%. Australia’s regulator trimmed liquidity requirements for Macquarie Bank after improvements in controls. Macquarie Asset Management announced two UK utility deals, including full ownership of Last Mile Infrastructure and the purchase of Energy Assets Group. Investors await Tuesday’s operational briefing.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 1:06 AM EST Crude Oil Prices Rise on Dollar Weakness, Geopolitical Tensions February 7, 2026, 12:52 AM EST. Crude oil prices edged higher on Friday, supported by a weaker U.S. dollar and escalating geopolitical risks in the Middle East. March WTI crude gained 0.41%, rebounding from early losses, while gasoline prices rose 1.38%. Doubts over a U.S.-Iran nuclear deal loom after reports of Iran's refusal to halt uranium enrichment, raising the risk of military action and potential disruption of vital shipping routes. Additionally, a surge in U.S. consumer
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Go toTop